Pimozide for schizophrenia or related psychoses Item Type Article Authors Rathbone, John Citation Rathbone, J. & McMonagle, T. (2007). Pimozide for schizophrenia or related psychoses. Cochrane Database of Systematic Reviews, (4), pp.1-220. Download date 24/09/2021 12:35:26 Link to Item http://hdl.handle.net/20.500.12904/9895 Cochrane Database of Systematic Reviews Pimozide for schizophrenia or related psychoses (Review) Mothi M, Sampson S Mothi M, Sampson S. Pimozide for schizophrenia or related psychoses. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD001949. DOI: 10.1002/14651858.CD001949.pub3. www.cochranelibrary.com Pimozide for schizophrenia or related psychoses (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 7 Figure1. ..................................... 8 OBJECTIVES ..................................... 8 METHODS ...................................... 8 Figure2. ..................................... 15 RESULTS....................................... 16 Figure3. ..................................... 17 Figure4. ..................................... 23 Figure5. ..................................... 24 Figure6. ..................................... 31 ADDITIONALSUMMARYOFFINDINGS . 39 DISCUSSION ..................................... 50 AUTHORS’CONCLUSIONS . 52 ACKNOWLEDGEMENTS . 53 REFERENCES ..................................... 54 CHARACTERISTICSOFSTUDIES . 61 DATAANDANALYSES. 120 Analysis 1.1. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 1 Global state: 1. Relapse - clinical diagnoses. 134 Analysis 1.2. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 2 Global state: 2. No improvement. 135 Analysis 1.3. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 3 Mental state: 1. Specific symptoms. 136 Analysis 1.4. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 4 Adverse effects: 1. Extrapyramidal adverse effects. .................................... 137 Analysis 1.5. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 5 Adverse effects: 2. Anticholinergic effects. 139 Analysis 1.6. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 6 Adverse effects: 3. Cardiovascular effects. 140 Analysis 1.7. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 7 Adverse effects: 4. Abnormal laboratory tests. 141 Analysis 1.8. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 8 Adverse effects: 5. Central nervous system effects. .................................... 142 Analysis 1.9. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 9 Adverse effects: 6. Dermatological effects. 143 Analysis 1.10. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 10 Adverse effects: 7. Endocrine effects. 143 Analysis 1.11. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 11 Adverse effects: 8. Gastrointestinal effects. 144 Analysis 1.12. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 12 Adverse effects: 9. Other. 145 Analysis 1.13. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 13 Leaving the study early: 1. Due to adverse effects. .................................... 147 Analysis 1.14. Comparison 1 PIMOZIDE versus PLACEBO, Outcome 14 Leaving the study early: 2. Any reason. 148 Analysis 2.1. Comparison 2 PIMOZIDE versus PLACEBO: withdrawal study, Outcome 1 Global state: 1. Relapse - clinicaldiagnoses. 149 Analysis 2.2. Comparison 2 PIMOZIDE versus PLACEBO: withdrawal study, Outcome 2 Mental state: 1. Use of additional medication. 149 Analysis 2.3. Comparison 2 PIMOZIDE versus PLACEBO: withdrawal study, Outcome 3 Adverse effects: 1. Death. 150 Analysis 2.4. Comparison 2 PIMOZIDE versus PLACEBO: withdrawal study, Outcome 4 Leaving the study early: 1. Any reason. .................................... 150 Analysis 3.1. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 1 Service utilisation: 1. Hospital admission.................................... 151 Analysis 3.2. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 2 Global state: 1. Relapse - clinical diagnoses. ................................... 152 Analysis 3.3. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 3 Global state: 2. No improvement................................... 153 Pimozide for schizophrenia or related psychoses (Review) i Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Analysis 3.4. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 4 Global state: 3. Average score - CGI(high=poor)................................. 154 Analysis 3.5. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 5 Mental state: 1. Average score - BPRS(high=poor). .. ... ... ... ... ... ... ... ... ... .. 154 Analysis 3.7. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 7 Mental state: 3. No improvement................................... 155 Analysis 3.8. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 8 Mental state: 4. Specific symptoms.................................... 156 Analysis 3.9. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 9 Mental state: 5. Use of additional medication. .................................. 157 Analysis 3.10. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 10 Adverse effects: 1. Extrapyramidal adverseeffects-specific. 158 Analysis 3.12. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 12 Adverse effects: 3. Death. 163 Analysis 3.13. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 13 Adverse effects: 4. Anticholinergic effects. .................................... 164 Analysis 3.14. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 14 Adverse effects: 5. Cardio- vasculareffects. ... ... ... ... ... ... ... ... ... ... .. 166 Analysis 3.15. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 15 Adverse effects: 6. Abnormal laboratorytests. ... ... ... ... ... ... ... ... ... ... .. 169 Analysis 3.16. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 16 Adverse effects: 7. Central nervoussystemeffects.. 171 Analysis 3.17. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 17 Adverse effects: 8. Dermatological effects. .................................... 175 Analysis 3.18. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 18 Adverse effects: 9. Endocrine effects. .................................... 176 Analysis 3.19. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 19 Adverse effects: 10. Gastrointestinaleffects. 177 Analysis 3.20. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 20 Adverse effects: 11. Genitourinaryeffects. 180 Analysis 3.21. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 21 Adverse effects: 12. Other. 181 Analysis 3.23. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 23 Leaving the study early: 1. Due torelapse. ................................... 183 Analysis 3.24. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 24 Leaving the study early: 2. Due toadverseeffects. 184 Analysis 3.25. Comparison 3 PIMOZIDE versus ANY ANTIPSYCHOTIC, Outcome 25 Leaving the study early: 3. Any reason. .................................... 185 Analysis 4.1. Comparison 4 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC, Outcome 1 Global state: 1. Relapse - clinical diagnoses. .......... 186 Analysis 4.2. Comparison 4 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC, Outcome 2 Leaving the study early: 1. Any reason. ....... 187 Analysis 5.2. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 2 Global state: 2. Average score - CGI-S (high = poor). ............ 188 Analysis 5.3. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 3 Global state: 3. Average score - CGI-I (high = poor). ............ 188 Analysis 5.4. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 4 Mental state: 1. Average score - BPRS (high = poor). ............ 189 Analysis 5.5. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 5 Mental state: 2. Average score - BPRS psychosis subscale (high = poor). 189 Analysis 5.7. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 7 Mental state: 4. Average score - SANS (high = poor). ............ 190 Analysis 5.8. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 8 Adverse effects: 1. Extrapyramidal adverse effects - specific. .............. 191 Pimozide for schizophrenia or related psychoses (Review) ii Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Analysis 5.10. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 10 Adverse effects: 3. Cardiovascular effects. ............. 192 Analysis 5.11. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 11 Adverse effects: 4. Cardiovascular effects - average score (high = poor). 193 Analysis 5.14. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome14Adverseeffects:7.Other. 195 Analysis 5.16. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 16 Leaving the study early: 1. Due to adverse effects. ................ 196 Analysis 5.17. Comparison 5 PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC + PLACEBO, Outcome 17 Leaving the study early: 2. Any reason. .......... 197 Analysis 6.1. Comparison 6 PIMOZIDE + ANY ANTIPSYCHOTIC versus